Sweet syndrome after treatment with vedolizumab in a patient with Crohn's disease

• Published in: Revista española de enfermedades digestivas Vol. 110; no. 8; p. 530
• Main Authors: Martínez Andrés, Blanca, Sastre Lozano, Violeta, Sánchez Melgarejo, José Francisco
• Format: Journal Article
• Language: English; Spanish
• Published: Spain Sociedad Espanola de Patologia Digestivas 01.08.2018
• Subjects: Adult; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Crohn Disease - complications; Crohn Disease - drug therapy; Gastrointestinal Agents - adverse effects; Gastrointestinal Agents - therapeutic use; Humans; Male; Skin - pathology; Sweet Syndrome - chemically induced
• ISSN: 1130-0108
• DOI: 10.17235/reed.2018.5603/2018

Sweet syndrome is a common extraintestinal manifestation in inflammatory bowel disease (IBD). In this research, a 42-year-old man case with colon Crohn's disease is been described. After failure with two anti-TNF therapies, in treatment with azathioprim, it was decided to start a therapeutic target change to Vedolizumab due to a severe outbreak refractory to corticosteroids. 24 hours after the infusion of the new drug, skin lesions appear along with leukocytes with neutrophilia, all suggestive of sweet syndrome later confirmed by histology. In this clinical case, the importance of knowing the possible side effects of recently commercialized drugs for IBD is shown, being this topic important for gastroenterologists due to the wide therapeutic arsenal that is becoming available for this pathology.